Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aldo Palange"'
Autor:
Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro, Patrizia Vici, Lorena Filomeno, Francesca Sofia Di Lisa, Teresa Arcuri, Eriseld Krasniqi, Alessandra Fabi, Annamaria Biroccio, Pasquale Zizza
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)
Abstract Background Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC form – is refract
Externí odkaz:
https://doaj.org/article/b5288dd001e444b193813380b0f2304e
Autor:
Fabiana Letizia Cecere, D. Assisi, Aldo Palange, Gennaro Ciliberto, Anna Di Benedetto, Claudia Bonomo, Simonetta Buglioni, Daniele Forcella, Paolo Visca, Edoardo Pescarmona, Cristiana Ercolani, Federico Cappuzzo, Irene Terrenato
Publikováno v:
Journal of Clinical Pathology. 75:844-850
AimsThe minimally invasive procedures used in the diagnostic workup of patients with advanced non-small cell lung cancer (NSCLC) often provide poor yields of pathological material suitable for molecular analyses. Not infrequently, the DNA yield from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff01c9c2a7469810c1814ea4623d518
https://doi.org/10.1136/jclinpath-2021-207726
https://doi.org/10.1136/jclinpath-2021-207726
Autor:
Cristiana, Ercolani, Anna, Di Benedetto, Claudia, Bonomo, Paolo, Visca, Aldo, Palange, Daniela, Assisi, Daniele, Forcella, Irene, Terrenato, Edoardo, Pescarmona, Gennaro, Ciliberto, Fabiana Letizia, Cecere, Federico, Cappuzzo, Simonetta, Buglioni
Publikováno v:
Journal of clinical pathology. 75(12)
The minimally invasive procedures used in the diagnostic workup of patients with advanced non-small cell lung cancer (NSCLC) often provide poor yields of pathological material suitable for molecular analyses. Not infrequently, the DNA yield from smal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b345072af477c1bfb867eda0dded85c9
https://pubmed.ncbi.nlm.nih.gov/34400544
https://pubmed.ncbi.nlm.nih.gov/34400544
Autor:
Irene Terrenato, Cristiana Ercolani, Anna Di Benedetto, Enzo Gallo, Elisa Melucci, Beatrice Casini, Francesca Rollo, Aldo Palange, Paolo Visca, Edoardo Pescarmona, Enrico Melis, Filippo Gallina, Andrea Sacconi, Fabiana Letizia Cecere, Lorenza Landi, Federico Cappuzzo, Gennaro Ciliberto, Simonetta Buglioni
Publikováno v:
Cancers; Volume 14; Issue 12; Pages: 2971
The approval of osimertinib for adjuvant treatment of stage I–II–III EGFR-mutated NSCLC (early stage) represents a paradigm shift, raising the question of whether other genotype-matched therapeutics approved for advanced-stage NSCLC can also prov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a31a93a83158eae4eb653bd975a0f6
https://doi.org/10.3390/cancers14122971
https://doi.org/10.3390/cancers14122971